Skip to main content

Principles of Pelvic Organ Prolapse Repair

Pelvic organ prolapse (POP) repair is a symptom-driven operation. Surgical decision-making is shaped by the location and severity of prolapse, symptom burden, patient health, patient preference, and surgeon expertise.[1] The framework below summarizes the contemporary evidence base — ACOG Practice Bulletin 214 anchors the clinical principles; SUPeR (NICHD Pelvic Floor Disorders Network, 2024) is the most important head-to-head trial of the modern era; the 2026 Cochrane updates frame anterior-compartment mesh and concomitant continence decisions; Ruffolo 2025 and Brennand 2025 anchor the hysteropexy-vs-hysterectomy debate.

Indications for Treatment​

  • Treatment is indicated only if prolapse is causing bothersome bulge / pressure symptoms, sexual dysfunction, lower urinary tract dysfunction, or defecatory dysfunction. Many women with POP on exam are asymptomatic and do not require intervention.[1]
  • A POP-Q examination is recommended before treatment for objective evaluation and documentation.[1]

Nonsurgical Management​

  • All symptomatic women should be offered a vaginal pessary as an alternative to surgery; up to 92% can be fitted successfully. Ring pessaries work best for stage II–III, while Gellhorn pessaries are more often needed for stage IV.[1][9]
  • Pelvic floor muscle exercises may improve symptoms or slow progression. Lifestyle modifications (fiber supplementation, osmotic laxatives, elevated seating) can address associated defecatory and bulge symptoms.[1][8]

Surgical Principles​

Vaginal approaches​

  • Vaginal hysterectomy alone is not adequate for uterine prolapse — vaginal apex suspension must be performed concurrently to reduce recurrent POP.[1]
  • Uterosacral and sacrospinous ligament suspension are equally effective native-tissue apical repairs, with comparable anatomic, functional, and adverse outcomes (2-year success ~64% for both).[1]
  • Anterior colporrhaphy is effective for most anterior wall prolapse, but concurrent apical support should be addressed, as many anterior defects have an apical component.[1]
  • Posterior colporrhaphy should be performed via midline plication without placing tension on the levator ani muscles (to avoid dyspareunia).[1]

Abdominal approaches​

  • Abdominal sacrocolpopexy (mesh from vaginal apex to sacral anterior longitudinal ligament) has a lower risk of recurrent POP but is associated with more complications than vaginal native-tissue repair. Candidates include those with shortened vaginal length, intra-abdominal pathology, or risk factors for recurrence (age <60, stage 3–4, BMI >26).[1][10]

Mesh and graft considerations​

  • Synthetic mesh or biologic grafts in transvaginal posterior wall repair do not improve outcomes.[1]
  • Polypropylene mesh augmentation of anterior wall repair improves anatomic outcomes but increases morbidity (mesh exposure ~12%, reoperation for mesh exposure ~8%).[1][3]
  • Transvaginal mesh should be limited to high-risk individuals (e.g., recurrent prolapse of anterior / apical compartments) after informed consent reviewing risks vs. native-tissue alternatives. Many older transvaginal mesh products have been withdrawn from the U.S. market.[1][3]

Uterine preservation​

  • Hysteropexy is a viable alternative to hysterectomy, with shorter operative time and lower mesh erosion risk, though less long-term evidence is available.[1][4][5]

Obliterative procedures​

  • Colpocleisis (vaginal closure) is effective and should be considered a first-line surgical option for women with significant comorbidities who do not desire vaginal preservation.[1]

Concomitant considerations​

  • Routine intraoperative cystoscopy is recommended during uterosacral ligament suspension, sacrocolpopexy, anterior colporrhaphy, and anterior / apical mesh placement.[1]
  • Preoperative evaluation for occult stress urinary incontinence (cough stress test or urodynamics with prolapse reduced) should be performed in all women with significant apical or anterior prolapse.[1][8]
  • Patients should be counseled that postoperative SUI is more likely without a concomitant continence procedure, but that an additional procedure increases adverse-event risk.[1][7]

Comparative Outcomes by Surgical Approach​

The landmark SUPeR trial (NICHD Pelvic Floor Disorders Network, 2024) directly compared three approaches for vaginal vault prolapse in 360 women. At 36 months, composite failure rates were 28% for sacrocolpopexy, 29% for transvaginal mesh, and 43% for native-tissue repair. Sacrocolpopexy was statistically superior to native-tissue repair (aHR 0.57, P = .01), and transvaginal mesh was noninferior to sacrocolpopexy (aHR 1.05). Mesh exposure rates were low: 3% for sacrocolpopexy and 5% for transvaginal mesh.[2]

A 2026 Cochrane review of anterior-compartment prolapse confirmed that native-tissue repair has higher recurrence than permanent mesh (recurrence 29–58% vs. 13% for mesh), but mesh carries increased risk of de novo stress urinary incontinence and bladder injury.[3] Many transvaginal mesh products evaluated in older trials have been withdrawn from the market, and only a few currently available kits have been studied.[3]

For posterior wall prolapse, evidence consistently shows that mesh or biologic grafts do not improve outcomes over native-tissue midline plication.[1]

Hysteropexy vs. Hysterectomy​

A 2025 meta-analysis of 16 studies (2,544 women) found no significant difference between vaginal hysterectomy and hysteropexy in apical recurrence (OR 0.60), global anatomic success, subjective success, or reoperation rates. Hysteropexy was associated with 29 minutes shorter operative time, 80 mL less blood loss, and 1.1 days shorter hospital stay.[4] A prospective cohort study (n = 321) similarly found lower composite recurrence with uterine preservation (adjusted RR 0.47) and fewer perioperative complications.[5]

For sacrocolpopexy patients in whom hysterectomy is performed concomitantly, a supracervical rather than total hysterectomy reduces mesh-exposure risk by retaining the cervix as the vaginal-apex anchor — see Supracervical Hysterectomy.

Concomitant Anti-Incontinence Procedures​

Occult stress urinary incontinence is common in women with POP because prolapse can kink and obstruct the urethra. The CARE and OPUS trials demonstrated that a prophylactic midurethral sling or Burch colposuspension at the time of prolapse repair reduces postoperative SUI (24% vs. 44–49%), though with increased adverse events (bladder perforation, voiding dysfunction).[6] A 2026 Cochrane review confirmed that a concomitant midurethral sling probably reduces postoperative SUI in women with symptomatic or occult SUI, but noted that a staged approach (sling only if needed postoperatively) is also feasible, as some women will not require it.[7]

Summary of Core Principles​

PrincipleKey Points
Treat only symptomatic prolapseIntervention for bothersome bulge, urinary / bowel / sexual dysfunction; asymptomatic POP requires only observation
Offer pessary before surgeryUp to 92% successfully fitted; low-risk alternative to surgery
Always address apical supportHysterectomy alone is inadequate; concurrent apex suspension reduces recurrence
Native-tissue repair is first-line for most primary POPLow-risk, no mesh complications; higher anatomic recurrence than mesh-augmented approaches
Sacrocolpopexy for durable apical repairSuperior anatomic outcomes vs. native tissue; consider for younger patients, advanced prolapse, recurrence
Restrict transvaginal mesh to select casesAnterior / apical recurrence or high-risk patients; informed consent required; many products withdrawn
Hysteropexy is a viable alternativeComparable outcomes to hysterectomy with less perioperative morbidity
Evaluate for occult SUI preoperativelyCough stress test with prolapse reduced; counsel on concomitant vs. staged continence procedure
Intraoperative cystoscopy when indicatedRequired for uterosacral suspension, sacrocolpopexy, anterior mesh placement
Obliterative surgery for select patientsColpocleisis effective for those not desiring vaginal preservation

References​

1. ACOG Practice Bulletin No. 214. "Pelvic Organ Prolapse." Obstet Gynecol. 2019;134(5):e126-e142. doi:10.1097/AOG.0000000000003519

2. Menefee SA, Richter HE, Myers D, et al. "Apical Suspension Repair for Vaginal Vault Prolapse: A Randomized Clinical Trial." JAMA Surg. 2024;159(8):845-855. doi:10.1001/jamasurg.2024.1206

3. Christmann-Schmid C, Baessler K, Yeung E, et al. "Surgery for Women With Anterior Compartment Prolapse." Cochrane Database Syst Rev. 2026;4:CD004014. doi:10.1002/14651858.CD004014.pub7

4. Ruffolo AF, Salvatore S, Torella M, et al. "The Uterus Debate in Vaginal Native Tissue Repair for Pelvic Organ Prolapse: Hysteropexy Versus Hysterectomy — A Systematic Review and Meta-Analysis." Maturitas. 2025;203:108755. doi:10.1016/j.maturitas.2025.108755

5. Brennand EA, Scime NV, Huang B, et al. "Hysterectomy Versus Uterine Preservation for Pelvic Organ Prolapse Surgery: A Prospective Cohort Study." Am J Obstet Gynecol. 2025;232(5):461.e1-461.e20. doi:10.1016/j.ajog.2024.10.021

6. ACOG Practice Bulletin No. 155. "Urinary Incontinence in Women." Obstet Gynecol. 2015;126(5):e66-e81. doi:10.1097/AOG.0000000000001148

7. Baessler K, Christmann-Schmid C, Haya N, et al. "Surgery for Women With Pelvic Organ Prolapse With or Without Stress Urinary Incontinence." Cochrane Database Syst Rev. 2026;2:CD013108. doi:10.1002/14651858.CD013108.pub2

8. Sung VW, Jeppson P, Madsen A. "Nonoperative Management of Pelvic Organ Prolapse." Obstet Gynecol. 2023;141(4):724-736. doi:10.1097/AOG.0000000000005121

9. Qiu J, Jiang D. "Pessaries for Managing Pelvic Organ Prolapse in Women." Am Fam Physician. 2021;103(11):660-661.

10. Siddiqui NY, Grimes CL, Casiano ER, et al. "Mesh Sacrocolpopexy Compared With Native Tissue Vaginal Repair: A Systematic Review and Meta-Analysis." Obstet Gynecol. 2015;125(1):44-55. doi:10.1097/AOG.0000000000000570